Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Lung Cancer

  Free Subscription


Articles published in Cancer Sci

Retrieve available abstracts of 109 articles:
HTML format
Text format



Single Articles


    August 2019
  1. KITA K, Fukuda K, Takahashi H, Tanimoto A, et al
    Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
    Cancer Sci. 2019 Aug 20. doi: 10.1111/cas.14171.
    PubMed     Text format     Abstract available


  2. MATSUMOTO Y, Sawa K, Fukui M, Oyanagi J, et al
    Impact of tumor microenvironment on the efficacy of EGFR-TKIs in patients with EGFR-mutant non-small cell lung cancer.
    Cancer Sci. 2019 Aug 1. doi: 10.1111/cas.14156.
    PubMed     Text format     Abstract available


  3. NUMANO T, Higuchi H, Alexander DB, Alexander WT, et al
    MWCNT-7 administered to the lung by intratracheal instillation induces development of pleural mesothelioma in F344 rats.
    Cancer Sci. 2019;110:2485-2492.
    PubMed     Text format     Abstract available


  4. KOTANI N, Yamaguchi A, Ohnishi T, Kuwahara R, et al
    Proximity proteomics identifies cancer cell membrane cis-molecular complex as a potential cancer target.
    Cancer Sci. 2019;110:2607-2619.
    PubMed     Text format     Abstract available


  5. KAGE H, Kohsaka S, Shinozaki-Ushiku A, Hiraishi Y, et al
    Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing.
    Cancer Sci. 2019;110:2652-2657.
    PubMed     Text format     Abstract available


  6. KIM Y, Shiba-Ishii A, Ramirez K, Muratani M, et al
    Carcinogen-induced tumors in SFN-transgenic mice harbor a characteristic mutation spectrum of human lung adenocarcinoma.
    Cancer Sci. 2019;110:2431-2441.
    PubMed     Text format     Abstract available


    July 2019
  7. KITAZONO S, Sakai K, Yanagitani N, Ariyasu R, et al
    Barcode sequencing identifies resistant mechanisms to EGFR-inhibitors in circulating tumor DNA of lung cancer patients.
    Cancer Sci. 2019 Jul 30. doi: 10.1111/cas.14153.
    PubMed     Text format     Abstract available


  8. MIAO W, Sakai K, Sato H, Imamura R, et al
    Impaired ligand-dependent MET activation caused by an extracellularSEMA domain missense mutation in lung cancer.
    Cancer Sci. 2019 Jul 24. doi: 10.1111/cas.14142.
    PubMed     Text format     Abstract available


  9. WU Y, Jamal M, Xie T, Sun J, et al
    Uridine-cytidine kinase 2 (UCK2): A potential diagnostic and prognostic biomarker for lung cancer.
    Cancer Sci. 2019 Jul 6. doi: 10.1111/cas.14125.
    PubMed     Text format     Abstract available


  10. HIRASHIMA T, Satouchi M, Hida T, Nishio M, et al
    Osimertinib for Japanese Patients with T790M-positive Advanced Non-Small Cell Lung Cancer: A Pooled Subgroup Analysis.
    Cancer Sci. 2019 Jul 2. doi: 10.1111/cas.14120.
    PubMed     Text format     Abstract available


  11. ITO T, Nakamura A, Tanaka I, Tsuboi Y, et al
    CADM1 associates with Hippo pathway core kinases; membranous co-expression of CADM1 and LATS2 in lung tumors predicts good prognosis.
    Cancer Sci. 2019;110:2284-2295.
    PubMed     Text format     Abstract available


  12. FAN CM, Wang JP, Tang YY, Zhao J, et al
    circMAN1A2 could serve as a novel serum biomarker for malignant tumors.
    Cancer Sci. 2019;110:2180-2188.
    PubMed     Text format     Abstract available


    June 2019
  13. CHEN H, Chong W, Teng C, Yao Y, et al
    The Immune Response-related Mutational Signatures and Driver Genes in Non-small Cell Lung Cancer.
    Cancer Sci. 2019 Jun 21. doi: 10.1111/cas.14113.
    PubMed     Text format     Abstract available


  14. LIANG W, Guo M, Pan Z, Cai X, et al
    Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibition.
    Cancer Sci. 2019;110:2014-2021.
    PubMed     Text format     Abstract available


  15. LI X, Zhu J, Liu Y, Duan C, et al
    MicroRNA-331-3p inhibits epithelial-mesenchymal transition by targeting ErbB2 and VAV2 through the Rac1/PAK1/beta-catenin axis in non-small-cell lung cancer.
    Cancer Sci. 2019;110:1883-1896.
    PubMed     Text format     Abstract available


    May 2019
  16. SONG L, Ma S, Chen L, Miao L, et al
    The long-term prognostic significance of IL-17 producing T cells in patients with non-small cell lung cancer.
    Cancer Sci. 2019 May 17. doi: 10.1111/cas.14068.
    PubMed     Text format     Abstract available


  17. YU S, Yang D, Ye Y, Liu P, et al
    lncRNA AFAP1-AS1 promotes malignant phenotype through binding with LSD1 and repressing HBP1 in non-small cell lung cancer.
    Cancer Sci. 2019 May 8. doi: 10.1111/cas.14039.
    PubMed     Text format     Abstract available


  18. HINO O, Abe M, Han B, Yan Y, et al
    In commemoration of the 2018 Mataro Nagayo Prize: A road to early diagnosis and monitoring of asbestos-related mesothelioma.
    Cancer Sci. 2019;110:1518-1524.
    PubMed     Text format     Abstract available


  19. TU W, Yang B, Leng X, Pei X, et al
    Testis-specific protein, Y-linked 1 activates PI3K/AKT and RAS signaling pathways through suppressing IGFBP3 expression during tumor progression.
    Cancer Sci. 2019;110:1573-1586.
    PubMed     Text format     Abstract available


  20. SUDO H, Tsuji AB, Sugyo A, Saga T, et al
    Therapeutic efficacy evaluation of radioimmunotherapy with (90) Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma.
    Cancer Sci. 2019;110:1653-1664.
    PubMed     Text format     Abstract available


    April 2019
  21. ANDO A, Hashimoto N, Sakamoto K, Omote N, et al
    Repressive role of stabilized HIF1alpha expression on TGFbeta-induced extracellular matrix production in lung cancer cells.
    Cancer Sci. 2019 Apr 20. doi: 10.1111/cas.14027.
    PubMed     Text format     Abstract available


  22. SAKAI K, Ohira T, Matsubayashi J, Yoneshige A, et al
    Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens.
    Cancer Sci. 2019 Apr 10. doi: 10.1111/cas.14016.
    PubMed     Text format     Abstract available


  23. MASUDA N, Ohe Y, Gemma A, Kusumoto M, et al
    Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.
    Cancer Sci. 2019;110:1401-1407.
    PubMed     Text format     Abstract available


    March 2019
  24. FURUTA M, Kikuchi H, Shoji T, Takashima Y, et al
    DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
    Cancer Sci. 2019 Mar 15. doi: 10.1111/cas.13997.
    PubMed     Text format     Abstract available


  25. WANG L, Li X, Ren Y, Geng H, et al
    Cancer-associated fibroblasts contribute to cisplatin resistance via modulating ANXA3 in lung cancer cells.
    Cancer Sci. 2019 Mar 13. doi: 10.1111/cas.13998.
    PubMed     Text format     Abstract available


  26. GUO R, Li Y, Wang Z, Bai H, et al
    HIF-1alpha and NF-kappaB play important roles in regulating PD-L1 expression by EGFR mutants in non-small cell lung cancer cells.
    Cancer Sci. 2019 Mar 7. doi: 10.1111/cas.13989.
    PubMed     Text format     Abstract available


  27. IEGUCHI K, Maru Y
    Roles of EphA1/A2 and ephrin-A1 in cancer.
    Cancer Sci. 2019;110:841-848.
    PubMed     Text format     Abstract available


  28. NISHIO M, Takahashi T, Yoshioka H, Nakagawa K, et al
    KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
    Cancer Sci. 2019;110:1012-1020.
    PubMed     Text format     Abstract available


  29. ZHA L, Kitamura Y, Kitamura T, Liu R, et al
    Population-based cohort study on health effects of asbestos exposure in Japan.
    Cancer Sci. 2019;110:1076-1084.
    PubMed     Text format     Abstract available


  30. MIYAUCHI E, Matsuda T, Kiyotani K, Low SK, et al
    Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations.
    Cancer Sci. 2019;110:867-874.
    PubMed     Text format     Abstract available


    February 2019
  31. SUKHBAATAR A, Mori S, Saiki Y, Takahashi T, et al
    Lymph node resection induces the activation of tumor cells in the lungs.
    Cancer Sci. 2019;110:509-518.
    PubMed     Text format     Abstract available


  32. YONEDA K, Kuwata T, Chikaishi Y, Mori M, et al
    Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma.
    Cancer Sci. 2019;110:726-733.
    PubMed     Text format     Abstract available


    January 2019
  33. WAHIDUZZAMAN M, Karnan S, Ota A, Hanamura I, et al
    Establishment and characterization of CRISPR/Cas9-mediated NF2(-/-) human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma.
    Cancer Sci. 2019;110:180-193.
    PubMed     Text format     Abstract available


  34. UCHIDA A, Seki N, Mizuno K, Misono S, et al
    Involvement of dual-strand of the miR-144 duplex and their targets in the pathogenesis of lung squamous cell carcinoma.
    Cancer Sci. 2019;110:420-432.
    PubMed     Text format     Abstract available


    December 2018
  35. PAN H, Peng Z, Lin J, Ren X, et al
    Forkhead box C1 boosts triple-negative breast cancer metastasis through activating the transcription of chemokine receptor-4.
    Cancer Sci. 2018;109:3794-3804.
    PubMed     Text format     Abstract available


  36. LIAO M, Liu Q, Li B, Liao W, et al
    A group of long noncoding RNAs identified by data mining can predict the prognosis of lung adenocarcinoma.
    Cancer Sci. 2018;109:4033-4044.
    PubMed     Text format     Abstract available


  37. IWAMA E, Sakai K, Azuma K, Harada D, et al
    Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.
    Cancer Sci. 2018;109:3921-3933.
    PubMed     Text format     Abstract available


  38. GU MM, Gao D, Yao PA, Yu L, et al
    p53-inducible gene 3 promotes cell migration and invasion by activating the FAK/Src pathway in lung adenocarcinoma.
    Cancer Sci. 2018;109:3783-3793.
    PubMed     Text format     Abstract available


    November 2018
  39. HAYASHI K, Yamamoto N, Nakajima M, Nomoto A, et al
    Clinical Outcomes of Carbon-Ion Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
    Cancer Sci. 2018 Nov 22. doi: 10.1111/cas.13890.
    PubMed     Text format     Abstract available


  40. NIU L, Song X, Wang N, Xue L, et al
    Tumor-derived exosomal proteins as diagnostic biomarkers in non-small cell lung cancer.
    Cancer Sci. 2018 Nov 8. doi: 10.1111/cas.13862.
    PubMed     Text format     Abstract available


  41. WATANABE S, Hayashi H, Haratani K, Shimizu S, et al
    Mutational activation of the EGFR down-regulates MHC class I expression via the ERK in non-small cell lung cancer.
    Cancer Sci. 2018 Nov 3. doi: 10.1111/cas.13860.
    PubMed     Text format     Abstract available


  42. KIMURA S, Tanaka K, Harada T, Liu R, et al
    Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay.
    Cancer Sci. 2018;109:3657-3661.
    PubMed     Text format     Abstract available


  43. TAKAHASHI Y, Shien K, Tomida S, Oda S, et al
    Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis.
    Cancer Sci. 2018;109:3634-3642.
    PubMed     Text format     Abstract available


  44. KIM IG, Lee JH, Kim SY, Hwang HM, et al
    Hypoxia-inducible transgelin 2 selects epithelial-to-mesenchymal transition and gamma-radiation-resistant subtypes by focal adhesion kinase-associated insulin-like growth factor 1 receptor activation in non-small-cell lung cancer cells.
    Cancer Sci. 2018;109:3519-3531.
    PubMed     Text format     Abstract available


    October 2018
  45. QIU L, Yu Q, Zhou Y, Zheng S, et al
    Functionally impaired Tfh cells induce regulatory B cells and CD14(+) HLA-DR(-) cells differentiation in non-small cell lung cancer.
    Cancer Sci. 2018 Oct 16. doi: 10.1111/cas.13836.
    PubMed     Text format     Abstract available


  46. HONG MJ, Yoo SS, Choi JE, Kang HG, et al
    A functional intronic variant of SLC5A10 affects DRG2 expression and survival outcomes of early-stage non-small cell lung cancer.
    Cancer Sci. 2018 Oct 3. doi: 10.1111/cas.13814.
    PubMed     Text format     Abstract available


  47. ZHAO X, Li X, Zhou L, Ni J, et al
    LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3.
    Cancer Sci. 2018;109:3068-3079.
    PubMed     Text format     Abstract available


  48. KATO Y, Ninomiya K, Ohashi K, Tomida S, et al
    Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Cancer Sci. 2018;109:3149-3158.
    PubMed     Text format     Abstract available


  49. LIU M, Jiang L, Fu X, Wang W, et al
    Cytoplasmic liver kinase B1 promotes the growth of human lung adenocarcinoma by enhancing autophagy.
    Cancer Sci. 2018;109:3055-3067.
    PubMed     Text format     Abstract available


  50. MAEMURA K, Watanabe K, Ando T, Hiyama N, et al
    Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma.
    Cancer Sci. 2018;109:3326-3335.
    PubMed     Text format     Abstract available


    September 2018
  51. ZHAO Y, Shao Q, Zhu H, Xu H, et al
    Resveratrol ameliorates Lewis lung carcinoma-bearing mice development, decreases granulocytic myeloid-derived suppressor cell accumulation and impairs its suppressive ability.
    Cancer Sci. 2018;109:2677-2686.
    PubMed     Text format     Abstract available


  52. HIDA T, Seto T, Horinouchi H, Maemondo M, et al
    Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9.
    Cancer Sci. 2018;109:2863-2872.
    PubMed     Text format     Abstract available


  53. YAMAMOTO Y, Miyazato K, Takahashi K, Yoshimura N, et al
    Lung-resident natural killer cells control pulmonary tumor growth in mice.
    Cancer Sci. 2018;109:2670-2676.
    PubMed     Text format     Abstract available


  54. PONGSUCHART M, Kuchimaru T, Yonezawa S, Tran DTP, et al
    Novel lymphoid enhancer-binding factor 1-cytoglobin axis promotes extravasation of osteosarcoma cells into the lungs.
    Cancer Sci. 2018;109:2746-2756.
    PubMed     Text format     Abstract available


    August 2018
  55. XU S, Lam SK, Cheng PN, Ho JC, et al
    Recombinant human arginase induces apoptosis via oxidative stress and cell cycle arrest in small cell lung cancer.
    Cancer Sci. 2018 Aug 28. doi: 10.1111/cas.13782.
    PubMed     Text format     Abstract available


  56. LIU YP, Chen CH, Yen CH, Tung CW, et al
    HIV Tat-TIP30 interaction promotes metastasis by enhancing the nuclear translocation of Snail in lung cancer cell lines.
    Cancer Sci. 2018 Aug 12. doi: 10.1111/cas.13768.
    PubMed     Text format     Abstract available


  57. SATO H, Yamamoto H, Sakaguchi M, Shien K, et al
    Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Cancer Sci. 2018 Aug 10. doi: 10.1111/cas.13763.
    PubMed     Text format     Abstract available


  58. GONG WJ, Liu JY, Yin JY, Cui JJ, et al
    Resistin facilitates metastasis of lung adenocarcinoma through the TLR4/Src/EGFR/PI3K/NF-kappaB pathway.
    Cancer Sci. 2018;109:2391-2400.
    PubMed     Text format     Abstract available


  59. ZHU Y, Tang L, Zhao S, Sun B, et al
    CXCR4-mediated osteosarcoma growth and pulmonary metastasis is suppressed by MicroRNA-613.
    Cancer Sci. 2018;109:2412-2422.
    PubMed     Text format     Abstract available


    July 2018
  60. LIU M, Zhang H, Li Y, Wang R, et al
    HOTAIR, a long non-coding RNA, is a marker of abnormal cell cycle regulation in lung cancer.
    Cancer Sci. 2018 Jul 26. doi: 10.1111/cas.13745.
    PubMed     Text format     Abstract available


  61. MURAKAMI H, Nokihara H, Hayashi H, Seto T, et al
    Clinical activity of ASP8273 in Asian patients with non-small cell lung cancer with EGFR activating and T790M mutations.
    Cancer Sci. 2018 Jul 4. doi: 10.1111/cas.13724.
    PubMed     Text format     Abstract available


  62. KAWASAKI N, Miwa T, Hokari S, Sakurai T, et al
    Long noncoding RNA NORAD regulates transforming growth factor-beta signaling and epithelial-to-mesenchymal transition-like phenotype.
    Cancer Sci. 2018;109:2211-2220.
    PubMed     Text format     Abstract available


    June 2018
  63. WATANABE M, Kenmotsu H, Ko R, Wakuda K, et al
    Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter.
    Cancer Sci. 2018 Jun 14. doi: 10.1111/cas.13692.
    PubMed     Text format     Abstract available


  64. QIN T, Huang D, Liu Z, Zhang X, et al
    TNFSF15 promotes lymphatic metastasis via up-regulation of VEGFC in a mouse model of lung cancer.
    Cancer Sci. 2018 Jun 11. doi: 10.1111/cas.13665.
    PubMed     Text format     Abstract available


  65. WANG H, Zhang G
    Endoplasmic reticulum stress-mediated autophagy protects against beta,beta-dimethylacrylshikonin-induced apoptosis in lung adenocarcinoma cells.
    Cancer Sci. 2018;109:1889-1901.
    PubMed     Text format     Abstract available


  66. ALAEE M, Nool K, Pasdar M
    Plakoglobin restores tumor suppressor activity of p53(R175H) mutant by sequestering the oncogenic potential of beta-catenin.
    Cancer Sci. 2018;109:1876-1888.
    PubMed     Text format     Abstract available


  67. FENG W, Xie Q, Liu S, Ji Y, et al
    Kruppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.
    Cancer Sci. 2018;109:1775-1786.
    PubMed     Text format     Abstract available


    May 2018
  68. AZUMA K, Nishio M, Hayashi H, Kiura K, et al
    ASP8273 tolerability and antitumor activity in TKI-naive Japanese patients with EGFR mutation-positive non-small cell lung cancer.
    Cancer Sci. 2018 May 28. doi: 10.1111/cas.13651.
    PubMed     Text format     Abstract available


  69. LI S, Ma F, Jiang K, Shan H, et al
    Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 promotes lung adenocarcinoma by directly interacting with specificity protein 1.
    Cancer Sci. 2018;109:1346-1356.
    PubMed     Text format     Abstract available


  70. LIU K, Gao H, Wang Q, Wang L, et al
    Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3 signaling in colorectal cancer.
    Cancer Sci. 2018;109:1369-1381.
    PubMed     Text format     Abstract available


  71. SEMBA T, Sugihara E, Kamoshita N, Ueno S, et al
    Periostin antisense oligonucleotide suppresses bleomycin-induced formation of a lung premetastatic niche for melanoma.
    Cancer Sci. 2018;109:1447-1454.
    PubMed     Text format     Abstract available


  72. HAYASHI K, Yamamoto N, Karube M, Nakajima M, et al
    Feasibility of carbon-ion radiotherapy for re-irradiation of locoregionally recurrent, metastatic, or secondary lung tumors.
    Cancer Sci. 2018;109:1562-1569.
    PubMed     Text format     Abstract available


    April 2018
  73. AKAMATSU H, Katakami N, Okamoto I, Kato T, et al
    Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small cell lung cancer: AURA3 trial.
    Cancer Sci. 2018 Apr 26. doi: 10.1111/cas.13623.
    PubMed     Text format     Abstract available


  74. WANG Y, Lei L, Zheng YW, Zhang L, et al
    Odd-skipped related 1 inhibits lung cancer proliferation and invasion by reducing Wnt signaling through the suppression of SOX9 and beta-catenin.
    Cancer Sci. 2018 Apr 16. doi: 10.1111/cas.13614.
    PubMed     Text format     Abstract available


  75. TANAKA I, Sato M, Kato T, Goto D, et al
    eIF2beta, a Subunit of Translation-Initiation Factor EIF2, Is a Potential Therapeutic Target for Non-Small Cell Lung Cancer.
    Cancer Sci. 2018 Apr 6. doi: 10.1111/cas.13602.
    PubMed     Text format     Abstract available


    March 2018
  76. WANG N, Song X, Liu L, Niu L, et al
    Circulating exosomes contain protein biomarkers of metastatic non-small-cell lung cancer.
    Cancer Sci. 2018 Mar 23. doi: 10.1111/cas.13581.
    PubMed     Text format     Abstract available


  77. TORIGOE H, Shien K, Takeda T, Yoshioka T, et al
    Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
    Cancer Sci. 2018 Mar 13. doi: 10.1111/cas.13571.
    PubMed     Text format     Abstract available


    February 2018
  78. XU Y, Ren H, Jiang J, Wang Q, et al
    KIAA0247 inhibits growth, migration, invasion of non-small-cell lung cancer through regulating the Notch pathway.
    Cancer Sci. 2018 Feb 16. doi: 10.1111/cas.13539.
    PubMed     Text format     Abstract available


  79. LI W, Zheng G, Xia J, Yang G, et al
    CREPT overexpression is associated with proliferation behaviors and poor prognosis in non-small cell lung cancer.
    Cancer Sci. 2018 Feb 3. doi: 10.1111/cas.13524.
    PubMed     Text format     Abstract available


  80. OHARA Y, Chew SH, Shibata T, Okazaki Y, et al
    Phlebotomy as a preventive measure for crocidolite-induced mesothelioma in male rats.
    Cancer Sci. 2018;109:330-339.
    PubMed     Text format     Abstract available


  81. LI P, Zhang L, Yu X, Tong R, et al
    Proliferation genes in lung development associated with the prognosis of lung adenocarcinoma but not squamous cell carcinoma.
    Cancer Sci. 2018;109:308-316.
    PubMed     Text format     Abstract available


    January 2018
  82. ZHANG Q, Yang J, Bai J, Ren J, et al
    Reverse of non-small cell lung cancer drug resistance induced by cancer associated fibroblasts via a paracrine pathway.
    Cancer Sci. 2018 Jan 30. doi: 10.1111/cas.13520.
    PubMed     Text format     Abstract available


  83. KIURA K, Yoh K, Katakami N, Nogami N, et al
    Osimertinib in patients with EGFR T790M advanced non-small cell lung cancer selected using cytology samples.
    Cancer Sci. 2018 Jan 24. doi: 10.1111/cas.13511.
    PubMed     Text format     Abstract available


  84. CHARVAT H, Sasazuki S, Shimazu T, Budhathoki S, et al
    Development of a risk prediction model for lung cancer: the Japan Public Health Center-based Prospective Study.
    Cancer Sci. 2018 Jan 18. doi: 10.1111/cas.13509.
    PubMed     Text format     Abstract available


  85. KATAYAMA R
    Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.
    Cancer Sci. 2018 Jan 16. doi: 10.1111/cas.13504.
    PubMed     Text format     Abstract available


  86. FAZIO N, Buzzoni R, Delle Fave G, Tesselaar ME, et al
    Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.
    Cancer Sci. 2018;109:174-181.
    PubMed     Text format     Abstract available


    December 2017
  87. CHENG HW, Chein RJ, Cheng TJ, Wu PS, et al
    The 2-anilino-4-amino-5-aroylthiazole-type compound AS7128 inhibits lung cancer growth through decreased iASPP and p53 interaction.
    Cancer Sci. 2017 Dec 29. doi: 10.1111/cas.13489.
    PubMed     Text format     Abstract available


    November 2017
  88. LIU J, Bian T, Feng J, Qian L, et al
    miR-335 inhibited cell proliferation of lung cancer cells by target Tra2beta.
    Cancer Sci. 2017 Nov 21. doi: 10.1111/cas.13452.
    PubMed     Text format     Abstract available


  89. ESAKI N, Ohkawa Y, Hashimoto N, Tsuda Y, et al
    ASCT2 defined by enzyme-mediated activation of radical sources enhances malignancy of GD2-plus small cell lung cancer.
    Cancer Sci. 2017 Nov 19. doi: 10.1111/cas.13448.
    PubMed     Text format     Abstract available


  90. OKABE H, Aoki K, Yogosawa S, Saito M, et al
    Downregulation of CD24 suppresses bone metastasis of lung cancer.
    Cancer Sci. 2017 Nov 2. doi: 10.1111/cas.13435.
    PubMed     Text format     Abstract available


  91. MAGARA K, Takasawa A, Osanai M, Ota M, et al
    Elevated expression of JAM-A promotes neoplastic properties of lung adenocarcinoma.
    Cancer Sci. 2017;108:2306-2314.
    PubMed     Text format     Abstract available


  92. DASSANO A, Pintarelli G, Cotroneo CE, Pettinicchio A, et al
    Complex genetic control of lung tumorigenesis in resistant mice strains.
    Cancer Sci. 2017;108:2281-2286.
    PubMed     Text format     Abstract available


    October 2017
  93. KATSURA M, Shoji F, Okamoto T, Shimamatsu S, et al
    Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients.
    Cancer Sci. 2017 Oct 15. doi: 10.1111/cas.13422.
    PubMed     Text format     Abstract available


  94. HUANG LX, Hu CY, Jing L, Wang MC, et al
    microRNA-219-5p inhibits epithelial-mesenchymal transition and metastasis of colorectal cancer by targeting lymphoid enhancer-binding factor 1.
    Cancer Sci. 2017;108:1985-1995.
    PubMed     Text format     Abstract available


  95. TAKITA J
    The role of anaplastic lymphoma kinase in pediatric cancers.
    Cancer Sci. 2017;108:1913-1920.
    PubMed     Text format     Abstract available


    September 2017
  96. LIU L, Liu J, Shao D, Deng Q, et al
    Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients.
    Cancer Sci. 2017 Sep 26. doi: 10.1111/cas.13410.
    PubMed     Text format     Abstract available


  97. CHI Y, Jin Q, Liu X, Xu L, et al
    The miR-203 inhibits cell proliferation, invasion, and migration of non-small cell lung cancer by downregulating RGS17.
    Cancer Sci. 2017 Sep 16. doi: 10.1111/cas.13401.
    PubMed     Text format     Abstract available


  98. MATSUBARA D, Soda M, Yoshimoto T, Amano Y, et al
    Inactivating mutations and hypermethylation of the NKX2-1/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas.
    Cancer Sci. 2017;108:1888-1896.
    PubMed     Text format     Abstract available


    August 2017
  99. KUTKOWSKA J, Strzadala L, Rapak A
    Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells.
    Cancer Sci. 2017 Aug 28. doi: 10.1111/cas.13386.
    PubMed     Text format     Abstract available


  100. INOUE Y, Matsuura S, Yoshimura K, Iwashita Y, et al
    Characterization of V-set and immunoglobulin domain containing 1 exerting a tumor suppressor function in gastric, lung, and esophageal cancer cells.
    Cancer Sci. 2017;108:1701-1714.
    PubMed     Text format     Abstract available


    July 2017
  101. OTSUBO K, Nosaki K, Imamura CK, Ogata H, et al
    Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small cell lung cancer.
    Cancer Sci. 2017 Jul 1. doi: 10.1111/cas.13309.
    PubMed     Text format     Abstract available


  102. GRIESING S, Kajino T, Tai MC, Liu Z, et al
    Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells.
    Cancer Sci. 2017;108:1394-1404.
    PubMed     Text format     Abstract available


  103. KUNIMASA K, Nagano T, Shimono Y, Dokuni R, et al
    Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
    Cancer Sci. 2017;108:1368-1377.
    PubMed     Text format     Abstract available


    May 2017
  104. TANIGUCHI H, Yamada T, Takeuchi S, Arai S, et al
    The impact of MET inhibition on small-cell lung cancer cells exhibiting aberrant activation of the HGF/MET pathway.
    Cancer Sci. 2017 May 5. doi: 10.1111/cas.13268.
    PubMed     Text format     Abstract available


    April 2017
  105. WANG R, Deng X, Yoshioka Y, Vougiouklakis T, et al
    Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small cell lung cancer cells.
    Cancer Sci. 2017 Apr 1. doi: 10.1111/cas.13245.
    PubMed     Text format     Abstract available


    March 2017
  106. SATO T, Shiba-Ishii A, Kim Y, Dai T, et al
    miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma.
    Cancer Sci. 2017;108:536-542.
    PubMed     Text format     Abstract available


  107. KUSUMOTO H, Shintani Y, Kanzaki R, Kawamura T, et al
    Podocalyxin influences malignant potential by controlling epithelial-mesenchymal transition in lung adenocarcinoma.
    Cancer Sci. 2017;108:528-535.
    PubMed     Text format     Abstract available


    February 2017
  108. KAMIOKA Y, Takakura K, Sumiyama K, Matsuda M, et al
    Intravital Forster resonance energy transfer imaging reveals osteopontin-mediated polymorphonuclear leukocyte activation by tumor cell emboli.
    Cancer Sci. 2017;108:226-235.
    PubMed     Text format     Abstract available


  109. KARASAKI T, Nagayama K, Kuwano H, Nitadori JI, et al
    Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.
    Cancer Sci. 2017;108:170-177.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: